Cancer Research and Treatment

Novel bioactive 2‐phenyl‐4‐aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non‐small cell lung cancer

Shidi Xu, Zhihui Zhou, Jie He, Jiaojiao Guo, Xiaoling Huang, Yufeng An, Qingshan Pan, Shan Xu, Wufu Zhu

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

Tae-Hwan Kim, Jin-Hyuk Choi, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Yong Won Choi, Young Wha Koh, Seung-Soo Sheen

A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam

Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review

Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, Floryane Kim, Timothée Olivier, Xiuning Le, Alfredo Addeo

Journal of Thoracic Oncology.2024;[Epub] CrossRef

Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea

Cliff Molife, Jae Min Cho, Jennifer Lapthorn, Min Ju Kang, Yulia D’yachkova, Sangmi Kim, Sam Colman, Saerom Kim, Agota Szende, Ji Hyun Park, Hee Kyung Ahn, Min Hee Hong, Kaisa-Leena Taipale, Hye Ryun Kim

Drugs - Real World Outcomes.2023; 10(1): 131. CrossRef

Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer

Pamela Soberanis Pina, Luis Lara-Mejía, Venecia Matias-Cruz, Feliciano Barrón, Andrés F. Cardona, Luis E. Raez, Eduardo Rios-Garcia, Oscar Arrieta

Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer

Gian Marco Leone, Saverio Candido, Alessandro Lavoro, Silvia Vivarelli, Giuseppe Gattuso, Daniela Calina, Massimo Libra, Luca Falzone

Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study

Vineeth Tatineni, Patrick J. O’Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia

Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma

Daniela Cárdenas-Fernández, Pamela Soberanis Pina, Jenny G. Turcott, Norberto Chávez-Tapia, Emilio Conde-Flores, Andrés F. Cardona, Oscar Arrieta

Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef

Design and synthesis of novel pyrazolopyrimidine candidates as promising EGFR-T790M inhibitors and apoptosis inducers

Ahmed A Gaber, Marwa Sharaky, Ayman Abo Elmaaty, Mohamed M Hammouda, Ahmed AE Mourad, Samy Y Elkhawaga, Mahmoud Mohamed Mokhtar, Amr S Abouzied, Mai AE Mourad, Ahmed A Al-Karmalawy

Future Medicinal Chemistry.2023; 15(19): 1773. CrossRef

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Huang‐Chih Chang, Chin‐Chou Wang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Yu‐Mu Chen, Yu‐Ping Chang, Chien‐Hao Lai, Wen‐Feng Fang, Meng‐Chih Lin, Hung‐Yi Chuang

Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence

Huang‐Chih Chang, Kuo‐Tung Huang, Chia‐Cheng Tseng, Yu‐Mu Chen, Chien‐Hao Lai, Yu‐Ping Chang, Yung‐Che Chen, Hung‐Yi Chuang, Chin‐Chou Wang

Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy

Medicinal Chemistry Research.2022; 31(1): 1. CrossRef

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang

Cancer Research and Treatment.2022; 54(2): 434. CrossRef

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Kuo, Ping-Chih Hsu, John Chang

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI

John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu

Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma

Martin Zapata Laguado, Andrea Zuluaga, Rafael Parra Medina, Ricardo Bruges

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands

Hong-Yi Zhao, Hai-Peng Wang, Yu-Ze Mao, Hao Zhang, Minhang Xin, Xiao-Xiao Xi, Hao Lei, Shuai Mao, Dong-Hui Li, San-Qi Zhang

Journal of Medicinal Chemistry.2022; 65(6): 4709. CrossRef

Cost-Effectiveness Analysis of Afatinib versus Gefitinib in Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Mutation in Indonesia: Observational studies with Retrospectives

Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati

Research Journal of Pharmacy and Technology.2022; : 1598. CrossRef

Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC

Clinical Medicine Insights: Oncology.2022; 16: 117955492211032. CrossRef

Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open‐Label, 2‐Period, Single‐Dose Crossover Study

Ping Shi, Xin Jiang, Ye Tao, Ting Li, Xin Li, Chenjing Wang, Yanping Liu, Yaping Ma, Xiaomeng Gao, Yu Cao

Clinical Pharmacology in Drug Development.2022; 11(10): 1177. CrossRef

Grb2 interacts with necrosome components and is involved in rasfonin-induced necroptosis

Bolin Hou, Haiwen Huang, Yueqian Li, Jingnan Liang, Zhijun Xi, Xuejun Jiang, Ling Liu, Erwei Li

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs

Hong-Yi Zhao, Xiao-Xiao Xi, Minhang Xin, San-Qi Zhang

Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity

Amr Sonousi, Rasha A. Hassan, Eman O. Osman, Amr M. Abdou, Soha H. Emam

Journal of Enzyme Inhibition and Medicinal Chemistry.2022; 37(1): 2644. CrossRef

Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations

Ming-Hung Chang, Kuo-Hwa Chiang, Jiunn-Min Shieh, Kuo-Chen Cheng, Chung-Han Ho

Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations

Kartik Sehgal, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa

Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A

Cheol‐Kyu Park, Sung‐Yong Lee, Jae Cheol Lee, Chang‐Min Choi, Shin Yup Lee, Tae‐Won Jang, In‐Jae Oh, Young‐Chul Kim

Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells

Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukher

Cancer Research and Treatment.2021; 53(2): 457. CrossRef

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort

Sheng-Kai Liang, Li-Ta Keng, Chia-Hao Chang, Yueh-Feng Wen, Meng-Rui Lee, Ching-Yao Yang, Jann-Yuan Wang, Jen-Chung Ko, Jin-Yuan Shih, Chong-Jen Yu

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Burak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, Emir Celik, Deniz Tataroglu Ozyukseler, Murat Ayhan, Tugba Basoglu, Aysegul Ilhan, Nadiye Akdeniz, Ahmet Gulmez, Izzet Dogan, Burak Yasin Aktas, Mustafa Gurbuz, Sinan Koca, Semra Paydas, Ali Murat Tatli

Journal of Cancer Research and Clinical Oncology.2021; 147(7): 2145. CrossRef

Gefitinib reduces oocyte quality by disturbing meiotic progression

Hong-Yong Zhang, Ying-Chun Ouyang, Jian Li, Chun-Hui Zhang, Wei Yue, Tie-Gang Meng, Heide Schatten, Qing-Yuan Sun, Wei-Ping Qian

Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study

Kristof Cuppens, Liesbet Lodewyckx, Ingel Demedts, Lore Decoster, Benoît Colinet, Koen Deschepper, Annelies Janssens, Daniella Galdermans, Thierry Pieters

Drugs - Real World Outcomes.2021; 8(2): 141. CrossRef

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

Shun Lu, Jin-Yuan Shih, Tae-Won Jang, Chong-Kin Liam, Yongfeng Yu

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment

Cheng-Yu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen, Shih-Chieh Chang

OncoTargets and Therapy.2021; Volume 14: 2301. CrossRef

EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations

Edward S Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James C-H Yang

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies

Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, BJ Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lu

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang

Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea

Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi‐Hyun Kim, Sung Yong Lee, Cheol‐Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation

Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen

Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?

Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Rolfo, Godefridus J. Peters, Elisa Giovannetti

Critical Reviews in Oncology/Hematology.2021; 166: 103454. CrossRef

Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer

Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yuji Okuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Cancer Management and Research.2021; Volume 13: 8297. CrossRef

Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Ziyu Wang, Xin Du, Ken Chen, Shanshan Li, Zhiheng Yu, Ziyang Wu, Li Yang, Dingding Chen, Wei Liu

EFIKASI TERAPI EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKIs) PADA KANKER PARU

Fitri Wulandari, Widyaningrum Utami, Evieta Rohana, Wimzy Rizqy Prabhata

Generics: Journal of Research in Pharmacy.2021;[Epub] CrossRef

Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: A retrospective cohort study in Taiwan

Yao‐Yu Hsieh, Wei‐Tse Fang, Yu‐Wen Lo, Yi‐Han Chen, Li‐Nien Chien

International Journal of Cancer.2020; 147(4): 1107. CrossRef

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Simon Heeke, Keunchil Park, Angela Märten, Edward S. Kim

Journal of Thoracic Oncology.2020; 15(5): 803. CrossRef

Anticancer activity evaluation of indazolyl-substituted piperidin-4-yl-aminopyrimidines

Chao Wang, Xiao-Wen Liu, Ting Xiao, Zhi-Qiang Xu, Shuang Cao, Hai-Feng Wang, Qiong-Jiao Yan, Shuang-Xi Gu, Yuan-Yuan Zhu

Medicinal Chemistry Research.2020; 29(5): 910. CrossRef

Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer

Xiao-yun Liu, Zi-tao Guo, Zhen-dong Chen, Yi-fan Zhang, Jia-lan Zhou, Yong Jiang, Qian-yu Zhao, Xing-xing Diao, Da-fang Zhong

Acta Pharmacologica Sinica.2020; 41(10): 1366. CrossRef

Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives

Giulia Sartori, Lorenzo Belluomini, Fiorella Lombardo, Alice Avancini, Ilaria Trestini, Emanuele Vita, Daniela Tregnago, Jessica Menis, Emilio Bria, Michele Milella, Sara Pilotto

Expert Review of Anticancer Therapy.2020; 20(7): 531. CrossRef

Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study

Ye Jiang, Wenli Chen, Weiguang Yu, Ning Shi, Guowei Han, Shuai Mao, Xinlei Zhang, Meiji Chen

Journal of International Medical Research.2020; 48(8): 030006052093709. CrossRef

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations

Shouzheng Wang, Puyuan Xing, Ke Yang, Xuezhi Hao, Di Ma, Yuxin Mu, Junling Li

Current Approaches in NSCLC Targeting K-RAS and EGFR

International Journal of Molecular Sciences.2019; 20(22): 5701. CrossRef